US$ 22.94
surmount-1 trial tirzepatide obesity without diabetes weight loss once weekly for the treatment of in people with type 2 (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Gastrointestinal tolerability and weight reduction
Description
Several similar nanoplatforms have demonstrated promise in optimizing antidiabetic therapy

Do not freeze reconstituted solution, as ice crystal formation can damage the peptide structure

Hold the vial horizontally and slowly rotate it back and forth

But Ill keep tracking things in my journal, and still write up weekly posts at least for this first month on 5mg (second month overall)

Additionally, GLP-1 drugs like tirzepatide reduce appetite, slow digestion, and may cause digestive side effects